Revenue of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Predicted to Achieve $3.22 Billion by 2030, Driven by 7.3% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
What was the valuation of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market in 2026, and what figure is it projected to hit by 2030?
The market for next-generation sequencing (NGS)-based molecular diagnostics has demonstrated robust expansion recently. This market is projected to expand from $2.26 billion in 2025 to $2.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this expansion has been driven by increased genetic disorder testing, advancements in high-throughput sequencing, heightened understanding of molecular diagnostics, greater use in clinical laboratories, and enhancements in sequencing reagent technology.
The next-generation sequencing (ngs)-based molecular diagnostics market size is projected to experience robust expansion over the coming years. This market is predicted to reach $3.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. Factors driving this growth during the forecast period include the incorporation of AI and machine learning into diagnostics, the proliferation of cloud-based genomic platforms, the creation of portable and point-of-care sequencing devices, an increase in personalized medicine uses, and partnerships between diagnostics and biotechnology companies. Key trends anticipated for the forecast period encompass AI-assisted molecular diagnostics, cloud-based genomic analysis platforms, portable sequencing technologies, the incorporation of bioinformatics pipelines, and swift detection of disease markers.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp
Which Drivers Are Affecting Market Participation In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
The expanding occurrence of infectious diseases is projected to drive the next-generation sequencing (NGS)-based molecular diagnostics market in the future. Infectious diseases are conditions caused by microorganisms like bacteria, viruses, fungi, or parasites that invade the body, multiply, and interfere with normal bodily functions. The prevalence of these diseases is increasing as greater travel and migration accelerate the spread of pathogens across regions and international boundaries. Next-generation sequencing (NGS)-based molecular diagnostics plays a crucial role in detecting infectious diseases by providing comprehensive and precise analysis of pathogens. It significantly reduces diagnostic time by identifying multiple microorganisms concurrently, thus enhancing treatment accuracy and patient care. For example, in February 2024, the UK Health Security Agency stated that tuberculosis cases in England surged to 4,850 in 2023, representing a 10.7% increase from 4,380 cases in 2022. Therefore, the rising incidence of infectious diseases is a primary catalyst for the growth of the next-generation sequencing (NGS)-based molecular diagnostics market.
What Segment Categories Are Covered In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
The next-generation sequencing (ngs)-based molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications
3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users
Subsegments:
1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware
2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents
3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services
4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits
Which Trends Are Expected To Influence The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market In The Upcoming Years?
Leading companies within the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on creating advanced NGS-based panels with the goal of enhancing the accuracy, accessibility, and efficiency of genetic testing. NGS panels are specific collections of genes or genomic regions analyzed simultaneously using NGS technology to detect clinically significant mutations, allowing for faster and more precise molecular diagnostics. As an illustration, in April 2024, Pillar Biosciences, a US-based diagnostics company, received FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit. This kit analyzes 22 clinically relevant genes in a single multiplex reaction. Designed for operation with Illumina’s MiSeq Dx system, the panel supports a sample-to-report time of approximately 48 hours and has the capacity to process up to 46 clinical samples per run. Furthermore, OncoReveal CDx includes companion diagnostic claims for KRAS (relevant for EGFR-targeted therapy in colorectal cancer) and EGFR (for TKI therapy in non–small-cell lung cancer), which facilitates a more comprehensive and efficient identification of actionable genomic alterations, ultimately improving clinical decision-making.
Which Leading Companies Dominate The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Share?
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28281&type=smp
Browse Through More Reports Similar to the Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market 2026, By The Business Research Company
Ngs Based Rna Sequencing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report
Next Generation Sequencing Market 2026
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-market
Point Of Care Molecular Diagnostics Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
